Overview
Diffuse intrinsic pontine glioma, often called DIPG, is a type of brain tumor that grows in the brainstem — specifically in a region called the pons. The pons is a critical part of the brain that controls many basic body functions, including breathing, heart rate, swallowing, eye movement, and balance. Because the tumor grows in a diffuse pattern, meaning it spreads throughout the tissue rather than forming a single lump, it cannot be safely removed with surgery. DIPG mainly affects children, typically between the ages of 5 and 10, though it can occur in younger children and teenagers as well. The tumor grows quickly and puts pressure on the brainstem, causing a range of serious symptoms. The most common early signs include problems with facial muscle control, difficulty walking, and double vision. As the tumor grows, children may develop weakness on one side of the body, trouble swallowing, and problems with speech. Treatment options for DIPG are very limited. Radiation therapy is the current standard of care and can temporarily shrink the tumor and relieve symptoms, but it does not cure the disease. Chemotherapy has not been shown to significantly improve outcomes in most cases. In recent years, researchers have discovered that most DIPG tumors carry a specific genetic change called the H3 K27M mutation, which has opened new doors for targeted therapies. Clinical trials are actively exploring new treatments, including ONC201, which has shown early promise for tumors with this mutation.
Also known as:
Key symptoms:
Double vision or crossed eyesDrooping eyelid or facial weakness on one sideDifficulty walking or loss of balanceWeakness or clumsiness in arms or legsTrouble swallowing or changes in speechHeadaches, especially in the morningNausea and vomitingFatigue and low energyChanges in behavior or personalityDifficulty controlling eye movementsHearing changesBreathing problems in advanced stages
Sporadic
Usually appears on its own, not inherited from a parent
Childhood
Begins in childhood, roughly ages 1 to 12
FDA & Trial Timeline
10 eventsM.D. Anderson Cancer Center — PHASE1
Washington University School of Medicine — PHASE1, PHASE2
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Nationwide Children's Hospital — PHASE2
Nationwide Children's Hospital — PHASE2
OX2 Therapeutics — PHASE1
Chulalongkorn University — PHASE1
Rigshospitalet, Denmark — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableModeyso
Treatment of adult and pediatric patients 2 years of age and older with H3 K27M-mutant diffuse glioma after prior radiotherapy. Dordaviprone is the first FDA-approved drug for this tumor type.
Rare Disease Specialist
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersChildren's Hospital of Philadelphia
📍 Philadelphia, Pennsylvania
👤 Study Director
👤 Richard Neibeger, MD
Ann & Robert H. Lurie Children's Hospital of Chicago
📍 Chicago, Illinois
Nationwide Children's Hospital
📍 Columbus, Ohio
University of Michigan
📍 Ann Arbor, Michigan
👤 Janssen Research & Development, LLC Clinicaltrial
University of Alabama at Birmingham
📍 Birmingham, Alabama
Johns Hopkins University
📍 Baltimore, Maryland
Seattle Children's Hospital
📍 Seattle, Washington
👤 Study Director
👤 Richard Neibeger, MD
Children's National Hospital
📍 Washington D.C., District of Columbia
Travel Grants
No travel grants are currently matched to Diffuse intrinsic pontine glioma.
Community
No community posts yet. Be the first to share your experience with Diffuse intrinsic pontine glioma.
Start the conversation →Latest news about Diffuse intrinsic pontine glioma
Disease timeline:
New recruiting trial: Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
New recruiting trial: Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Does my child's tumor have the H3 K27M mutation, and what does that mean for treatment options?,Are there any clinical trials that my child might be eligible for?,What are the goals of radiation therapy, and what side effects should we expect?,When should we involve palliative care, and what does that involve?,How will we know if the tumor is responding to treatment or growing again?,What support services — such as physical therapy, speech therapy, or psychological support — are available for our family?,Should we seek a second opinion at a specialized DIPG center?
Common questions about Diffuse intrinsic pontine glioma
What is Diffuse intrinsic pontine glioma?
Diffuse intrinsic pontine glioma, often called DIPG, is a type of brain tumor that grows in the brainstem — specifically in a region called the pons. The pons is a critical part of the brain that controls many basic body functions, including breathing, heart rate, swallowing, eye movement, and balance. Because the tumor grows in a diffuse pattern, meaning it spreads throughout the tissue rather than forming a single lump, it cannot be safely removed with surgery. DIPG mainly affects children, typically between the ages of 5 and 10, though it can occur in younger children and teenagers as well
How is Diffuse intrinsic pontine glioma inherited?
Diffuse intrinsic pontine glioma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Diffuse intrinsic pontine glioma typically begin?
Typical onset of Diffuse intrinsic pontine glioma is childhood. Age of onset can vary across affected individuals.
Are there clinical trials for Diffuse intrinsic pontine glioma?
Yes — 20 recruiting clinical trials are currently listed for Diffuse intrinsic pontine glioma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Diffuse intrinsic pontine glioma?
25 specialists and care centers treating Diffuse intrinsic pontine glioma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.